A new publication involving vasoactive intestinal peptide (VIP) appeared in the journal Brain and Behavior on September 1, 2026. The study, titled "Serum VIP and IL-1β Levels Are Associated With Anxiety and Depression in Patients With Parkinson's Disease: A Cross-Sectional Study," was published under PubMed ID 42677804. The publication describes a cross-sectional study design examining serum levels of VIP and IL-1β in patients with Parkinson's disease. According to the title, the study relates these serum measurements to anxiety and depression in this patient population. No additional findings, statistics, or conclusions beyond the publication's title have been provided. This entry reflects only the fact that the publication exists and its stated title, journal, and date. Readers interested in the broader context of VIP, including its regulatory status and general background, can consult the compound overview.
New Publication Examines Serum VIP Levels in Parkinson's Patients
See the full vasoactive intestinal peptide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42677804/